On March, 21 The EPS for Knight Therapeutics Inc. (GUD) Expected At $0.03

Knight Therapeutics Inc. (TSE:GUD) Corporate Logo

On March, 21. Investors expect Knight Therapeutics Inc. (TSE:GUD) to reveal its quarterly earnings, according to RTT. Analysts have expectation on stock’s EPS of $0.03. That’s down 40.00 % from last year’s $0.05 EPS. In case of $0.03 EPS T_GUD’s profit could reach $4.29M. After $0.03 EPS report last quarter, Wall Street now forecasts 0.00 % EPS growth of Knight Therapeutics Inc.. GUD hit $7.55 during the last trading session after $0.02 change.Knight Therapeutics Inc. has volume of 251,818 shares. Since March 15, 2018 GUD has 0.00% and is . The stock underperformed the S&P 500 by 4.37%.

Knight Therapeutics Inc., a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally.The firm is worth $1.08 billion. The company's commercialized products include Impavido, an alkyllysophospholipid analogue drug for the treatment of visceral and cutaneous Leishmaniasis; Movantik for the treatment of opioid induced constipation; AzaSite to treat bacterial conjunctivitis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Flat Tummy Tea, a herbal detox tea; and FOCUSfactor, a dietary supplement.The P/E ratio is 34.79. The Company’s products under development comprise Probuphine to treat opioid addiction; NeurAxon family to treat acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; Iluvien to treat diabetic macular edema; and Netildex to treat ocular inflammation.

More recent Knight Therapeutics Inc. (TSE:GUD) news were released by Theglobeandmail.com, Theglobeandmail.com and Seekingalpha.com. The first one has “The week’s most oversold and overbought stocks on the TSX – The Globe and Mail” as a title and was released on December 28, 2018. The next is “Knight Therapeutics Inc (GUD-T) Quote – The Globe and Mail” on November 15, 2017. And last was released on November 09, 2016, called “Knight Therapeutics: The Outsider CEO You’ve Never Heard Of – Seeking Alpha”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.